- Home
- NSP vs RARE Comparison
NSP vs RARE Comparison
Compare NSP & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSP
- RARE
- Stock Information
- Founded
- NSP 1986
- RARE 2010
- Country
- NSP United States
- RARE United States
- Employees
- NSP N/A
- RARE N/A
- Industry
- NSP Professional Services
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- NSP Consumer Discretionary
- RARE Health Care
- Exchange
- NSP Nasdaq
- RARE Nasdaq
- Market Cap
- NSP 2.4B
- RARE 2.8B
- IPO Year
- NSP 1997
- RARE 2014
- Fundamental
- Price
- NSP $60.37
- RARE $27.34
- Analyst Decision
- NSP Hold
- RARE Strong Buy
- Analyst Count
- NSP 3
- RARE 15
- Target Price
- NSP $80.00
- RARE $87.40
- AVG Volume (30 Days)
- NSP 396.5K
- RARE 3.1M
- Earning Date
- NSP 08-01-2025
- RARE 08-04-2025
- Dividend Yield
- NSP 3.97%
- RARE N/A
- EPS Growth
- NSP N/A
- RARE N/A
- EPS
- NSP 1.65
- RARE N/A
- Revenue
- NSP $6,642,000,000.00
- RARE $590,689,000.00
- Revenue This Year
- NSP $4.83
- RARE $18.94
- Revenue Next Year
- NSP $5.99
- RARE $28.61
- P/E Ratio
- NSP $36.73
- RARE N/A
- Revenue Growth
- NSP 1.90
- RARE 33.46
- 52 Week Low
- NSP $56.36
- RARE $25.81
- 52 Week High
- NSP $104.90
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- NSP 51.45
- RARE 32.88
- Support Level
- NSP $56.36
- RARE $25.81
- Resistance Level
- NSP $57.99
- RARE $28.52
- Average True Range (ATR)
- NSP 1.55
- RARE 1.66
- MACD
- NSP 0.40
- RARE -0.43
- Stochastic Oscillator
- NSP 67.06
- RARE 9.24
About NSP Insperity Inc.
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.